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egorical regression model. First the estimation procedure was
validated through estimation of the MAUF for the EQ-5D
attributes based on the exiting Spanish tariff scores for the instru-
ment. Secondly the MAUF for the SF-6D attributes was esti-
mated regressed on the EQ-5D tariff scores. Weights were
rescaled to yield scores ranging from worse possible state (0) to
full health (1). RESULTS: All estimated attribute weights were
signiﬁcant and goodness of ﬁt was reasonable (R2 = 0.799).
Spanish utility values for the same health states are signiﬁcantly
different from those used in the UK; 0.7458 (0.208) vs. 0.7090
(0.143), p < 0.001. The shape of utility scores obtained with the
Spanish MAUF exhibits a cubic pattern as compared to the
British. Utilities obtained by the Spanish MAUF are higher for
benign health states while severe states attain lower utilities.
CONCLUSION: The proposed method allows for a valid and
reliable estimation of a MAUF based on kwon utilities of a
concurrent instrument, avoiding the need of incomplete designs
to collect preferences. Evident differences between culture
speciﬁc scoring systems encourage adapting instruments to the
target culture in order to obtain valid measures. Spanish weights
for SF-6D are now available to be used with existing or new
SF-36v1 databases.
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OBJECTIVES: The efﬁcacy and safety of certolizumab pegol
(CZP), a PEGylated anti-TNF, in patients with active Crohn’s
disease (CD) have been demonstrated in two 26-week induction
and maintenance trials, PRECiSE 1 (Sandborn et al., 2005) and
PRECiSE 2 (Schreiber et al., 2005). This analysis evaluated the
effect of CZP versus placebo on quality-adjusted life-years
(QALYs) for each subject in these trials. METHODS: In
PRECiSE 1, patients with active CD received double-blind CZP
400 mg (n = 331) or placebo (n = 328) every 4 weeks after induc-
tion. PRECiSE 2 began with an open-label induction period
(CZP 400 mg at Weeks 0, 2 and 4). Patients who demonstrated
a clinical response at Week 6 were randomised to receive CZP
400 mg (n = 215) or placebo (n = 210) every 4 weeks from
Weeks 8 to 24. The EQ-5D was administered at each visit and
converted into utility scores using an established algorithm
(Dolan et al., 1995). An estimate of QALYs was made for each
patient from the area under the utility curve during the randomi-
sation period of each trial. Mean QALYs and standard deviation
(SD) were calculated by treatment group and compared using a
Wilcoxon rank sum test. RESULTS: Over the 26-week PRECiSE
1 trial, the mean (SD) QALYs were 0.5456 (0.2993) for CZP and
0.4797 (0.3121) for placebo. Similarly, between Weeks 6 and 26
of PRECiSE 2, the mean (SD) QALYs were 0.4976 (0.2047) in
the CZP group versus 0.4286 (0.2171) in the three injection
followed by placebo group. A statistically signiﬁcant gain in
QALYs with CZP was observed in both trials: PRECiSE 1 0.0659
(p = 0.001); PRECiSE 2 0.0690 (p = 0.015). CONCLUSION:
CZP improved both quality and quantity of remission and
response period, as measured by QALYs, signiﬁcantly more than
placebo among patients with CD in two 26-week maintenance
trials.
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OBJECTIVES: Non-steroidal anti-inﬂammatory drugs (NSAIDs)
and Aspirin are among the most widely used drugs, particularly
for long-term treatment of arthritic disorders in primary care.
Aspirin/NSAIDs cause upper-gastrointestinal symptoms. This
study aimed to assess the nature and frequency of Upper-GI
symptoms (GERD and/or Dyspepsia) experienced by patients
receiving Aspirin and/or NSAIDs and to depict the current clini-
cal practice in the ﬁeld of gastroprotection of patients receiving
these drugs. METHODS: A total of 1604 individuals (M/F:
743/861, age 58.3713.1 years, BMI 27.5  3.7 Kg/m2) visiting
189 Primary Care Practitioners between June-July 2006 were
included. A structured questionnaire was used to record
demographic/medical history data including Aspirin/NSAIDs
use, the antisecretory treatment received together with Aspirin/
NSAIDs and the presence of GERD (heartburn, regurgitation)
and Dyspepsia (epigastric pain, early satiety, postprandial full-
ness) symptoms, which were based on widely accepted epidemio-
logical criteria. RESULTS: The main indications for patients
receiving Aspirin/NSAIDs were backache (16.7%), osteoarthritis
(14.5%), coronary artery disease (8.9%) and rheumatoid arthri-
tis (5.6%). Upper-GI symptoms (GERD and/or Dyspepsia) for
2 days/week were reported by 71.7% of participants. GERD
was reported by 57.3% and Dyspepsia by 54.8% of participants,
while 40.3% of them experienced symptoms of both diseases.
Antisecretory treatment was used by 78.8% of participants (PPIs
75.8%, H2-antagonists 20.2%, Antacids 8.2%). Upper-GI
symptoms of 2 day’s per/week were reported by 70.5% of
patients who received antisecretory treatment compared to
76.8% of those who did not (P < 0.025). Patients receiving
PPI experienced upper-GI symptoms by 66.2%, signiﬁcantly
less compared to 83.9% of H2-antagonists/Antacids users
(P < 0.001). CONCLUSION: Upper-GI symptoms are present in
approximately 3/4 of Aspirin/NSAIDs users. Antisecretory treat-
ment reduces Upper-GI symptoms, with PPIs being signiﬁcantly
superior than H2–antagonists/Antacids. However, in primary
care, a substantial proportion of Aspirin/NSAIDs users remain
symptomatic despite the use of antisecratory agents and therefore
other parameters such as adherence to antisecratory treatment
should be further investigated.
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OBJECTIVES: To estimate demand and supply of blood prod-
ucts in Bavaria, as due to intransparency on prices and trade
volumes reliable data are missing and to support optimal plan-
ning of blood supply and usage in Bavaria within the next two
decades. METHODS: Data were collected through desk-top
researches on demographics (e.g. Federal Statistical Ofﬁce
Germany, Bavarian State Ofﬁce for Statistics and Data Process-
ing), blood usage and donation behaviour in Germany (Robert
Koch Institute, Paul-Ehrlich-Institute, Bavarian Red Cross) and
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disease-related information, e.g. epidemiology, frequency of
interventions (Federal Health Monitoring, German Foundation
Organ Transplantation, German Index for Stem Cell Transplan-
tation, Literature). RESULTS: Bavarian demand for blood prod-
ucts of approximately 2,850 units per workday (750,000 units
per year) was estimated. Potential blood donators add up to
approximately 8,474 million people. Assuming a donation rate
of 3% an approx. number of 250,000 donators exist. Most
active segment of donators is between 32–56 years. It will be
affected by the demographic shift, means a declining population
of approximatelt 425,000 people in this segment. Stem cell trans-
plantations (+50% in the last 7 years) and organ transplantations
(+15% in 2005) lead to an increasing demand of blood products.
Statistical data show an increasing life expectancy of 5 years until
2050 (male 81.1/female 86.6 years) entailing higher cancer inci-
dence rates (+50% until 2050) affecting blood consumption
(20% of all blood products are used in cancer therapies). The
German blood market volume for the year 2005 is estimated to
be €500 mill. For the Bavarian sub-segment a value of €75
million can be deducted. CONCLUSION: Further research and
survey will be necessary to derive strategic recommendations for
the blood market participants. Then a dynamic population
model will be developed to project future effects on blood
demand and supply.
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OBJECTIVES: Health Intervention and Technology Assessment
program (HITAP), a newly established Health Technology
Assessment (HTA) agency in Thailand, has tried to develop the
systematic, transparent, and participatory mechanisms for HTA
topic selection. An overall aim of this study was to describe
quantitatively and qualitatively progression and ﬁndings from
HTA topic selection process recently developed by HITAP.
METHODS: The process involved potential users of HTA infor-
mation namely 1) public health insurers; 2) national health policy
makers; and 3) HITAP public funding organizations. In Decem-
ber 2006, these key players were invited to submit the topics
needed to be assessed based on their considerations. The submit-
ted topics were reviewed and prioritised by HITAP researchers in
January 2007 using several preset criteria. Furthermore, a con-
sultation workshop was conducted and the representatives from
those organisations submitted the HTA topics provide justiﬁca-
tions and prioritize their own list of top ten HTA topics needed
to be assessed in 2007. Results from each organisation were
analysed and the ﬁnal list made by workshop participants were
compared with the list made by HITAP researchers. RESULTS:
Fifty-one topics were submitted from ten organisations.
However, only 29 distinct HTA topics were met inclusion criteria
and then included in the priority setting process. Most topics
were pharmaceuticals (51%), medical procedures (24%),
medical devices (15%) and health policy (10%). At ﬁnal, six out
of ten topics selected by HITAP researchers were the same as
those made by the representatives from public health authorities.
CONCLUSION: Findings from this study illustrated the possi-
bility to make HTA topic selection process to be systematic,
transparent and participatory, which would eventually increase
the usefulness and credibility of HTA.
PHP3
BUDGET SILO MENTALITY BEHINDTHE FORMER IRON
CURTAIN:A CASE STUDY FROM HUNGARY
Boncz I1, Gulácsi L2, Sebestyén A3
1University of Pécs, Pécs, Hungary, 2Corvinus University of Budapest,
Budapest, Hungary, 3National Health Insurance Fund Administration,
Pécs, Hungary
OBJECTIVES: Between 1994–2006 the budget for pharmaceu-
tical reimbursement of the Hungarian National Health Insurance
Fund Administration (OEP), the only health care ﬁnancing
agency in Hungary, showed signiﬁcant deﬁcit. It means that the
actual drug expenditures became much higher at the end of the
year as it was originally planned at the beginning of the ﬁscal
year. The aim of the study to analyse the drug budget of the OEP
by identifying the pattern of this deﬁcit. METHODS: Data
derived from the ﬁnancial database of the Hungarian National
Health Insurance Fund Administration, covering the period
1994–2006. We analysed the planned and the actual drug budget
focusing on the deﬁcit. Deﬁcit was calculated as follows: dividing
the gap between the planned and the actual budget by the actual
budget. RESULTS: In each year between 1994–2006 we found a
deﬁcit at the drug budget of the OEP. This deﬁcit varied between
2.8% (lowest, 1996) and 36.6% (highest, 2006) of total actual
expenditures. We found 4 peaks on the diagram showing the
deﬁcit in the following years: 1994 (21.5%), 1998 (32.1%),
2002 (36.6%) and 2006 (30.4%). In each of these years, both
national governmental and local elections were held in Hungary.
CONCLUSION: We found deﬁcit in the drug budget of the
Hungarian OEP in each year between 1994–2006, however the
highest deﬁcit occurred in those years with political elections.
Such strong coincidence between political elections and drug
budget should be omitted as soon as possible in order to provide
a more transparent way of drug reimbursement policy.
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OBJECTIVES: To compare Canadian brand and generic drug
prices and U.S. generic drug prices for ten months following U.S.
brand patent expiration and to bring attention to a growing
source of competition during a generic company’s 180-day mar-
keting exclusivity period. METHODS: The Canada/U.S. Internet
Pharmacy Drug Price Database contains weekly prices since
January 2005 of more than 50 prescription medications from
eight Canadian and ﬁve U.S. on-line pharmacies. Ten months of
pricing data ($US) were extracted and compared for the Cana-
dian and U.S. brand and generic versions of sertraline and sim-
vastatin following U.S. patent expiration in 2006. RESULTS:
During the ﬁrst six months after U.S. patent expiration, the
average prices of brand and generic sertraline 100 mg from
Canadian on-line pharmacies were 11.4 and 45.5 percent less,
respectively, than the price of generic sertraline from U.S. on-line
pharmacies. Canadian brand and generic simvastatin 20 mg were
32.2 and 60.4% less expensive, respectively, than U.S. generic
simvastatin. At the tenth month post U.S. patent expiration, the
average price of the Canadian brand product exceeded that of the
U.S. generic product for both sertraline (by 15.8%) and simvas-
tatin (by 35.2%). However, Canadian generic products were still
less expensive than U.S. generic products (sertraline, 34.3% less;
simvastatin, 41.6% less). Prices for U.S. generic sertraline and
simvastatin dropped an average of ﬁve and 14 percent monthly,
respectively, after the exclusivity period. CONCLUSION: U.S.
generic drugs can be more expensive than both brand and generic
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